Sunitinib: all 340 studies that test it

Page 1 of 4. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.

• A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaRecruitingNCT07477457Phase 2
• Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid TumorsRecruitingNCT06940349Phase 1/2
• Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant TreatmentNot yet recruitingNCT06032728Not applicable
• OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNot yet recruitingNCT05949424Phase 4
• Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsRecruitingNCT05687123Phase 1
• ctDNA-Guided Sunitinib And Regorafenib Therapy for GISTRecruitingNCT05366816Phase 2
• Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Phase 1/2
• Losartan + Sunitinib in Treatment of OsteosarcomaRecruitingNCT03900793Phase 1
• Pan Tumor Rollover StudyRecruitingNCT03899155Phase 2
• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2
• A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant TreatmentNot yet recruitingNCT02688491Not applicable
• Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)Active, not recruitingNCT06390826Phase 2Results posted
• A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein OcclusionCompletedNCT04085341Phase 2Results posted
• A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMDCompletedNCT03953079Phase 2Results posted
• Sunitinib in Sarcomas of the Central Nervous SystemTerminatedNCT03641326Phase 2Results posted
• Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise TestingCompletedNCT03109015Phase 2Results posted
• Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has ProgressedCompletedNCT02761057Phase 2Results posted
• Personalized Targeted Inhibitors Treatment in Renal Cell CancerTerminatedNCT02560012Phase 2Results posted
• A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic TumoursCompletedNCT02402062Phase 2Results posted
• CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid TumorsCompletedNCT02401815Phase 1/2Results posted
• Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive SurgeryTerminatedNCT02315625Phase 2Results posted
• Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GISTCompletedNCT02164240Phase 1Results posted
• Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)CompletedNCT02060370Phase 2Results posted
• Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney CancerCompletedNCT01835158Phase 2Results posted
• Sunitinib in Never-Smokers With Lung AdenocarcinomaCompletedNCT01829217Phase 2Results posted
• Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney CancerTerminatedNCT01740154Not applicableResults posted
• Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney CancerCompletedNCT01664182Phase 2Results posted
• Sunitinib for Advanced Thymus Cancer Following Earlier TreatmentCompletedNCT01621568Phase 2Results posted
• Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaTerminatedNCT01620216Phase 2Results posted
• A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine TumorsCompletedNCT01525550Phase 4Results posted
• Phase II Study of Alternating Sunitinib and TemsirolimusCompletedNCT01517243Phase 2Results posted
• PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell CarcinomaTerminatedNCT01502228Not applicableResults posted
• Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)CompletedNCT01472081Phase 1Results posted
• Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or EpendymomaCompletedNCT01462695Phase 2Results posted
• Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform NeurofibromasTerminatedNCT01402817Phase 2Results posted
• A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal TumorCompletedNCT01396148Phase 2Results posted
• Sunitinib or Cediranib for Alveolar Soft Part SarcomaCompletedNCT01391962Phase 2Results posted
• Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic MalignanciesCompletedNCT01306045Phase 2Results posted
• A Phase 1b Trial in Patients With Renal Cell CancerCompletedNCT01258348Phase 1Results posted
• Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted TherapiesCompletedNCT01254864Phase 2Results posted
• Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver CancerCompletedNCT01164202Phase 2/3Results posted
• Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney CancerCompletedNCT01158222Phase 2Results posted
• Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine TumorsCompletedNCT01121562Phase 2Results posted
• Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder CancerTerminatedNCT01118351Phase 2Results posted
• Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell CarcinomaCompletedNCT01108445Phase 2Results posted
• Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney CancerCompletedNCT01064310Phase 3Results posted
• Evaluation of Patients With Bulky GIST Using SunitinibTerminatedNCT01054911Not applicableResults posted
• Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and CystectomyTerminatedNCT01042795Phase 2Results posted
• A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell CarcinomaTerminatedNCT00982657Phase 2Results posted
• Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian CancerCompletedNCT00979992Phase 2Results posted
• Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell CarcinomaTerminatedNCT00975806Phase 1/2Results posted
• Sunitinib and Capecitabine for First Line Colon CancerTerminatedNCT00961571Phase 2Results posted
• Sunitinib to Treat Recurrent Brain CancerTerminatedNCT00923117Phase 2Results posted
• Sunitinib Malate in Refractory Germ Cell TumorsTerminatedNCT00912912Phase 2Results posted
• Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain MetastasesTerminatedNCT00910039Phase 2Results posted
• Exemestane With Sunitinib (SUTENT®) in Metastatic Breast CancerTerminatedNCT00905021Phase 1/2Results posted
• Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell CarcinomaCompletedNCT00903175Phase 2Results posted
• Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal JunctionCompletedNCT00891878Phase 2Results posted
• Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast CancerCompletedNCT00887575Phase 1/2Results posted
• Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer PatientsTerminatedNCT00879619Phase 1/2Results posted
• Sunitinib Non Small Cell Lung Cancer Patients Over 70CompletedNCT00864721Phase 2Results posted
• Sunitinib in Certain Subtypes of Soft Tissue SarcomasTerminatedNCT00859456Phase 2Results posted
• Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCCTerminatedNCT00859339Phase 2Results posted
• AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With SunitinibCompletedNCT00853372Phase 2Results posted
• Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney CancerTerminatedNCT00853125Phase 2Results posted
• Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney CancerCompletedNCT00849186Not applicableResults posted
• Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder CancerCompletedNCT00847015Phase 2Results posted
• Study Of Sunitinib In Patients With Recurrent Paraganglioma/PheochromocytomaCompletedNCT00843037Phase 2Results posted
• Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone MarrowTerminatedNCT00824538Phase 2Results posted
• Gemzar, Cisp, Sunitinib Urothelial CaCompletedNCT00821327Phase 2Results posted
• Rollover Protocol for Prior SU011248 ProtocolsCompletedNCT00798889Not applicableResults posted
• Trial of Sunitinib for Refractory Malignant AscitesTerminatedNCT00796861Phase 2Results posted
• Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial CarcinomaCompletedNCT00794950Phase 2Results posted
• Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal TumorCompletedNCT00793871Phase 4Results posted
• Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver CancerTerminatedNCT00787787Phase 2Results posted
• Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal CarcinomaCompletedNCT00768144Phase 2Results posted
• Multimodality Phase II Study in Prostate CancerTerminatedNCT00734851Phase 2Results posted
• A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid MalignanciesCompletedNCT00732992Phase 1Results posted
• Sutent + Taxol for Advanced Esophageal CancerCompletedNCT00730353Phase 2Results posted
• Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid TumorsTerminatedNCT00729833Phase 1Results posted
• Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell CarcinomaCompletedNCT00706706Phase 4Results posted
• Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or LymphomaCompletedNCT00705874Phase 1Results posted
• Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction CancerCompletedNCT00702884Phase 2Results posted
• Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver CancerTerminatedNCT00699374Phase 3Results posted
• Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung CancerCompletedNCT00698815Phase 2Results posted
• Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung CancerCompletedNCT00695292Phase 2Results posted
• Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor ResponseCompletedNCT00694096Phase 1Results posted
• Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination ChemotherapyCompletedNCT00693992Phase 3Results posted
• Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel ChemotherapyTerminatedNCT00676650Phase 3Results posted
• Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau SyndromeTerminatedNCT00673816Phase 1/2Results posted
• Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to ProstatectomyCompletedNCT00672594Phase 2Results posted
• Study Of Sunitinib With FOLFIRI In Colorectal CancerCompletedNCT00668863Phase 2Results posted
• Sutent Adjunctive Treatment of Differentiated Thyroid CancerCompletedNCT00668811Phase 2Results posted
• Study Of Sunitinib With Capecitabine In Breast CancerCompletedNCT00662025Phase 2Results posted
• Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast CancerCompletedNCT00656669Not applicableResults posted
• Study Of Sunitinib In Combination With Folfox In Patients With Colorectal CancerCompletedNCT00631410Phase 1Results posted
• Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLCCompletedNCT00616109Phase 2Results posted
• Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal CancerTerminatedNCT00609622Phase 2Results posted

← Sunitinib overview